Monte Rosa Therapeutics Stock Today

GLUE Stock  USD 4.32  0.26  6.40%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 60

 
High
 
Low
Above Average
Monte Rosa is trading at 4.32 as of the 12th of July 2024, a 6.40 percent increase since the beginning of the trading day. The stock's lowest day price was 4.09. Monte Rosa has more than 60 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Monte Rosa Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of June 2024 and ending today, the 12th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of June 2021
Category
Healthcare
Classification
Health Care
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the bodys natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics, Inc. The company has 61.15 M outstanding shares of which 2.56 M shares are currently shorted by private and institutional investors with about 7.62 trading days to cover. More on Monte Rosa Therapeutics

Moving together with Monte Stock

  0.91VRDN Viridian Therapeutics Buyout TrendPairCorr
  0.62VTYX Ventyx BiosciencesPairCorr

Moving against Monte Stock

  0.65VRAX Virax Biolabs GroupPairCorr
  0.64PFE Pfizer Inc Aggressive PushPairCorr
  0.43XWEL XWELL IncPairCorr
  0.37MRK Merck Company Financial Report 6th of August 2024 PairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Monte Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO PresidentMarkus MD
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities26.9 M46.6 M
Way Down
Slightly volatile
Non Current Liabilities Total46.9 M77.9 M
Way Down
Slightly volatile
Total Assets236 M303.8 M
Significantly Down
Slightly volatile
Total Current Assets201.1 M236.2 M
Fairly Down
Slightly volatile
Debt Levels
Monte Rosa can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Monte Rosa's financial leverage. It provides some insight into what part of Monte Rosa's total assets is financed by creditors.
Liquidity
Monte Rosa Therapeutics currently holds 46.04 M in liabilities with Debt to Equity (D/E) ratio of 0.16, which may suggest the company is not taking enough advantage from borrowing. Monte Rosa Therapeutics has a current ratio of 19.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Monte Rosa's use of debt, we should always consider it together with its cash and equity.

Investments

21.59 Million
Monte Rosa Therapeutics (GLUE) is traded on NASDAQ Exchange in USA. It is located in 321 Harrison Avenue, Boston, MA, United States, 02118 and employs 130 people. Monte Rosa is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 248.27 M. Monte Rosa Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.15 M outstanding shares of which 2.56 M shares are currently shorted by private and institutional investors with about 7.62 trading days to cover. Monte Rosa Therapeutics currently holds about 294.14 M in cash with (43.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Monte Rosa Probability Of Bankruptcy
Ownership Allocation
Monte Rosa Therapeutics maintains a total of 61.15 Million outstanding shares. The majority of Monte Rosa outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Monte Rosa Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Monte Rosa Therapeutics. Please pay attention to any change in the institutional holdings of Monte Rosa as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Monte Ownership Details

Monte Stock Institutional Holders

InstituionRecorded OnShares
Casdin Capital, Llc2024-03-31
510.9 K
Northern Trust Corp2024-03-31
290.5 K
Exoduspoint Capital Management, Lp2024-03-31
265.3 K
Charles Schwab Investment Management Inc2024-03-31
250.6 K
Td Asset Management Inc2024-03-31
193.2 K
Millennium Management Llc2024-03-31
150 K
Renaissance Technologies Corp2024-03-31
122.1 K
Wellington Management Company Llp2024-03-31
120.6 K
Manufacturers Life Insurance Co2024-03-31
103.1 K
Nea Management Company, Llc2024-03-31
7.7 M
Fmr Inc2024-03-31
5.3 M
View Monte Rosa Diagnostics

Monte Rosa Historical Income Statement

At present, Monte Rosa's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 4.5 M, whereas Gross Profit is projected to grow to (5.9 M). View More Fundamentals

Monte Stock Against Markets

Monte Rosa Corporate Management

Filip MDChief OfficerProfile
Jennifer ChampouxVP OperationsProfile
Sharon TownsonChief OfficerProfile
Edmund DunnVice ControllerProfile
John CastleChief ScientistProfile
Magnus DPHILSenior DevelopmentProfile

Additional Information and Resources on Investing in Monte Stock

When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.51)
Revenue Per Share
0.02
Return On Assets
(0.31)
Return On Equity
(0.68)
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.